NEUWAY Pharma GmbH Names Dr. Oliver Ernst Managing Director, Chief Operating Officer

Bonn, February 25, 2019 - NEUWAY Pharma announced today the appointment of Dr. Oliver Ernst as Managing Director and Chief Operating Officer. Dr. Ernst brings many years of experience in the management of intellectual property rights (IP) in the area of software-based medical technology, pharmaceuticals, and biotechnology, as well as the development of a sustainable, business-related IP strategy. Dr. Ernst previously worked in one of Germany's leading innovative medical technology companies, in the biotech industry, as well as in a Europe-wide-leading patent law firm.

Dr. Ernst will replace Dr. Scherhag as planned, who is retiring in June 2019. Dr. Scherhag will continue to be a shareholder and consultant for NEUWAY.

The most important professional stages of Dr. Ernst career were between 2013 and 2018 at Brainlab AG where he successfully set up and managed a department for the management of industrial property rights (IP) and was increasingly entrusted with tasks of general management. Dr. Ernst particularly focused on the definition and implementation of a client and competitive IP strategy, including portfolio valuation and restructuring, building a sustainable IP portfolio, competitive / technology scouting and IP risk valuation in the areas of research and development (R & D), mergers and acquisitions (M & A), business development as well as licensing and capitalization strategy of IP assets.

Dr. Ernst previously worked in the patent department of BASF Plant Science, Ghent and at an international patent attorney's office.

"We are very pleased, to have Dr. Oliver Ernst join NEUWAY", Dr. Heiko Manninga, co-founder, Managing Director and Chief Scientific Officer of NEUWAY. "With his experience and ambition, he will significantly advance the progress of our company and help us to further accelerate the development into an internationally leading Brain Delivery Company. I'm really looking forward to working with him. "

Dr. Rainer Strohmenger, NEUWAY Advisory Board Chairman and General Partner at Wellington Partners, added, "Because of his entrepreneurial personality and his diverse international experience in the area of intellectual property rights and business development in neurology, I am convinced that Dr. Ernst will make a decisive contribution to the success of NEUWAY's innovative CNS drug delivery technology. On behalf of the Advisory Board and all partners, I would like to thank Dr. Scherhag for all his excellent work."

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Platform. The company also intends to partner its drug delivery technology for application to proprietary compounds of pharmaceutical companies to exploit their therapeutic use in the field of CNS indications.

NEUWAY Pharma GmbH
Ludwig-Erhard-Allee 2
53175 Bonn
Press Contact:
Christine Kuhn, +49-(0)228-522198-0, kuhn@neuway-pharma.com
www.neuway-pharma.com

This release was published on openPR.